Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women

In Vivo

Volumn 24, Issue 2, 2010, Pages 243-248

  Rukset, Attar ^a   Bedia, Agachan ^b   Sibel, Bulgurcuoglu Kuran ^b   Canan, Cacina ^b   Seyma, Sozen ^b   Leman, Melis Yurdum ^b   Erkut, Attar And ^c   Turgay, Isbir ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CCL2; CCR2; Chemokines; Endometrial cancer; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC);

EID: 77950606656     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Brooks N and Pouniotis DS: Immunomodulation in endometrial cancer. Int J Gynecol Cancer 19(4): 734-740, 2009.
2. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4(7): 540-550, 2004.
3. Karnoub AE and Weinberg RA: Chemokine networks and breast cancer metastasis. Breast Dis 26: 75-85, 2006-2007. (Pubitemid 46647416)
4. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation, N Engl J Med 338: 436-445, 1998.
5. Struyf S, Proost P and Van Damme J: Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 81: 1-44, 2003. (Pubitemid 38009040)
6. Vandercappellen J, Van Damme J and Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett 267: 226-244, 2008.
7. Rossi D and Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242, 2000.
8. Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev 13(2): 143-154, 2002.
9. Melgarejo E, Medina, MÁ, Sánchez-Jiménez F and Urdiales JL: Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 41(5): 998-1001, 2009.
10. Rovin BH, Lu L and Saxena R: A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259: 344-348, 1999. (Pubitemid 29281234)
11. Amann B, Perabo FG, Wirger A, Hugenschmidt H and Schultze-Seemann W: Urinary levels of monocyte chemoattractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br J Urol 82: 118-121, 1998. (Pubitemid 28316680)
12. Riethdorf L, Riethdorf S, Gutzlaff K, Prall F and Loning T: Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol 149: 1469-1476, 1996. (Pubitemid 26363953)
13. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R and Rosl F: Monocyte chemoattractant protein-1 (MCP-1) gene expression in cervical intraepithelial neoplasias and cervical carcinomas. Int J Cancer 82: 6-11, 1999.
14. Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, Allavena P, Sozzani S, Mantovani A and Balkwill FR: The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 95: 2391-2396, 1995.
15. Negus RP, Stamp GW, Hadley J and Balkwill FR: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of CC chemokines. Am J Pathol 150: 1723-1734, 1997. (Pubitemid 27193819)
16. Wong MP, Cheung KN, Yuen ST, Fu KH, Chan AS, Leung SY and Chung LP: Monocyte chemoattractant protein-1 (MCP-1) expression in primary lymphoepithelioma-like carcinomas (LELCs) of the lung. J Pathol 186: 372-377, 1998.
17. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Iannettoni MD and Strieter RM: Macrophage infiltration in human non-small cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother 49: 63-70, 2000. (Pubitemid 30431641)
18. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R and Jonjic N: Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194: 335-340, 1998. (Pubitemid 28291370)
19. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6: 3282-3289, 2000. (Pubitemid 30637758)
20. Smith MW, Carrington M, Winkler C, Lomb D, Dean M, Huttley G and O'Brien SJ: CCR2 chemokine receptor and AIDS progression. Nat Med 3: 1052-1053, 1997. (Pubitemid 27444420)
21. Kostrikis L, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU and Ho DD: A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 4: 350-353, 1998. (Pubitemid 28144097)
22. Miller SA, Dykes DD and Polesky HF: Simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988
23. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabó T, Nagy B, Horváth L and Császár A: Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518G/G genotype in CAD patients. Atherosclerosis 158: 233-239, 2001.
24. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL and McDermott DH: Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13: 754-758, 2002. (Pubitemid 34183942)
25. Barrett JC, Fry B, Maller J and Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265, 2005. (Pubitemid 40202029)
26. Mehrabian M, Sparkes RS, Mohandas T, Fogelman AM and Lusis AJ: Localization of- monocyte chemotactic protein-1 gene (SCYA2) to human chromosome 17q11.2-q21.1. Genomics 9: 200-203, 1991.
27. Yoshie O, Imai T and Nomiyama H: Chemokines in immunity. Adv Immunol 78: 57-110, 2001.
28. Mackay CR: Chemokines: what chemokine is that? Curr Biol 7: 384-386, 1997.
29. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z and Zhang J: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. The Prostate 66(12): 1311-1318, 2006. (Pubitemid 44384308)
30. Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q and Zhang J: Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia 11(3): 228-236, 2009.
31. Das A and Yan L: Anti CCL-2/MCP-1: Directed biologicals for inflammatory and malignant diseases.Target Validation in Drug Discovery Chapter 6: 103-119, 2007.
32. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z and Zhang J: CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101(3): 676-685, 2007. (Pubitemid 46698852)
33. Salcedo R, Ponce ML, Young HA Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ and Murphy WJ: Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96(1): 34-40, 2000. (Pubitemid 30456447)
34. Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B and Van Riet I: Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 88(6): 855-862, 2003. (Pubitemid 36520872)
35. Janis K, Hoeltke J, Nazareth M, Fanti P, Poppenberg K and Aronica SM: Estrogen decreases expression of chemokine receptors, and suppresses chemokine bioactivity in murine monocytes. Am J Reprod Immunol 51(1): 22-31, 2004. (Pubitemid 38190328)
36. Lebrecht A, Hefler L, Tempfer C and Koelbl H: Serum cytokine concentrations in patients with cervical cancer: interleukin-4, interferon-gamma, and monocyte chemoattractant protein-1. Gynecol Oncol 83(1): 170-171, 2001. (Pubitemid 32959899)
37. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A and Kainz C: Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81(5): 855-859, 1999. (Pubitemid 29504697)
38. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T and Kerin MJ: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13(17): 5020-5027, 2007. (Pubitemid 47502066)
39. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E and Koelbl H: Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25(1-2): 14-17, 2004. (Pubitemid 38822766)
40. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr, Larson MG, Vasan RS, Hirschhorn JN, O'Donnell CJ, Murphy PM and Benjamin EJ: CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112: 1113-1120, 2005.
41. Luo Y, Chen X and O'Donnell MA: Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 147: 370-378, 2007. (Pubitemid 46096016)
42. Daughterly BL and Springer MS: The beta-chemokine receptor genes CCR1 (CMKBR1), CCR2 (CMKBR2), and CCR3 (CMKBR3) cluster within 285 kb on human chromosome 3p21. Genomics 41: 294-295, 1997.
43. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE and Charo IF: Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100(10): 2552-2561, 1997. (Pubitemid 27514895)
44. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C and Rollins BJ: Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187(4): 601-608, 1998. (Pubitemid 28093362)
45. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A and Shioda T: A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 18: 729-738, 2004. (Pubitemid 38535000)
46. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, Martinez-A C, O'Brien SJ, Dean M, Collman RG and Doms RW: Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 co-receptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 72: 7450-7458, 1998. (Pubitemid 28377876)
47. Ortlepp JR, Krantz C, Kimmel M, von Korff A, Vesper K, Schmitz F, Mevissen V, Janssens U, Franke A, Hanrath P, Zerres K and Hoffmann R: Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. Int J Cardiol 105: 90-95, 2005. (Pubitemid 41406366)
48. Petrkova J, Cermakova Z, Drabek J, Lukl J and Petrek M: CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett 88: 53-55, 2003. (Pubitemid 36835850)
49. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A and Kawakami Y: The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 159: 2021-2023, 1999. (Pubitemid 29275080)
50. Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S and Tashiro K: C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 145: 135-138, 2003. (Pubitemid 37485974)
51. Shrestha S, Strathdee SA, Galai N, Oleksyk T, Fallin MD, Mehta S, Schaid D, Vlahov D, O'Brien SJ and Smith MW: Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 193(1): 16-26, 2006. (Pubitemid 43033317)
52. Zafiropoulos A, Crikas N, Passam AM and Spandidos DA: Significant involvement of CCR2-64I and CXCLI2-3a in the development of sporadic breast cancer. J Med Genet 41: 59, 2004.